Uterine corpus endometrial carcinoma (UCEC) is the third most frequent gynecological malignancies in the female reproductive system. Long non-coding RNAs (lncRNAs) are closely involved in tumor progression. This study aimed to develop an immune subtyping system and a prognostic model based on lncRNAs for UCEC. Paired lncRNAs and non-negative matrix factorization were applied to identify immune subtypes. Enrichment analysis was conducted to assess functional pathways, immune-related genes, and cells. Univariate and multivariate Cox regression analysis were performed to analyze the relation between lncRNAs and overall survival (OS). A prognostic model was constructed and optimized by least absolute shrinkage and selection operator (LASSO) and Akaike information criterion (AIC). Two immune subtypes (C1 and C2) and four paired-prognostic lncRNAs closely associated with overall survival were identified. Some immune features, sensitivity of chemotherapy and immunotherapy, and the relation with immune escape showed variations between two subtypes. A nomogram established based on prognostic model and clinical features was effective in OS prediction. The immune subtyping system based on lncRNAs and the four-paired-lncRNA signature was predictive of UCEC prognosis and can facilitate personalized therapies such as immunotherapy or RNA-based therapy for UCEC patients.
SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalABrayF.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA2021;
71:209–49
2.
KandothCSchultzNCherniackADAkbaniRLiuYShenHRobertsonAGPashtanIShenRBenzCCYauCLairdPWDingLZhangWMillsGBKucherlapatiRMardisERLevineDA.Integrated genomic characterization of endometrial carcinoma. Nature2013;
497:67–73
3.
LeDTDurhamJNSmithKNWangHBartlettBRAulakhLKLuSKemberlingHWiltCLuberBSWongFAzadNSRuckiAALaheruDDonehowerRZaheerAFisherGACrocenziTSLeeJJGretenTFDuffyAGCiomborKKEyringADLamBHJoeAKangSPHoldhoffMDanilovaLCopeLMeyerCZhouSGoldbergRMArmstrongDKBeverKMFaderANTaubeJHousseauFSpetzlerDXiaoNPardollDMPapadopoulosNKinzlerKWEshlemanJRVogelsteinBAndersRADiazLAJr.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science2017;
357:409–13
4.
GreenAKFeinbergJMakkerV.A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book2020;
40:1–7
5.
OttPABangYJBerton-RigaudDElezEPishvaianMJRugoHSPuzanovIMehnertJMAungKLLopezJCarriganMSarafSChenMSoriaJC.Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol2017;
35:2535–41
6.
MarcusLLemerySJKeeganPPazdurR.FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res2019;
25:3753–8
7.
AroraSBalasubramaniamSZhangWZhangLSridharaRSpillmanDMathaiJPScottBGoldingSJCooryMPazdurRBeaverJA.FDA approval summary: pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project orbis. Clin Cancer Res2020;
26:5062–7
8.
MakkerVTaylorMHAghajanianCOakninAMierJCohnALRomeoMBratosRBroseMSDiSimoneCMessingMStepanDEDutcusCEWuJSchmidtEVOrlowskiRSachdevPShumakerR,
Casado Herraez A. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol2020;
38:2981–92
9.
HowittBEShuklaSAShollLMRitterhouseLLWatkinsJCRodigSStoverEStricklandKCD'AndreaADWuCJMatulonisUAKonstantinopoulosPA.Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol2015;
1:1319–23
10.
BhanASoleimaniMMandalSS.Long noncoding RNA and cancer: a new paradigm. Cancer Res2017;
77:3965–81
11.
JiangMCNiJJCuiWYWangBYZhuo W.Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res2019;
9:1354–66
12.
LiBLWanXP.The role of lncRNAs in the development of endometrial carcinoma. Oncol Lett2018;
16:3424–9
13.
GuptaRAShahNWangKCKimJHorlingsHMWongDJTsaiMCHungTArganiPRinnJLWangYBrzoskaPKongBLiRWestRBvan de VijverMJSukumarSChangHY.Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature2010;
464:1071–6
YanXHuZFengYHuXYuanJZhaoSDZhangYYangLShan WHeQFanLKandalaftLETanyiJLLiCYuanCXZhangDYuanHHuaKLuYKatsarosDHuangQMontoneKFanYCoukosGBoydJSoodAKRebbeckTMillsGBDangCVZhangL.Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell2015;
28:529–40
16.
BeroukhimRMermelCHPorterDWeiGRaychaudhuriSDonovanJBarretinaJBoehmJSDobsonJUrashimaMMc HenryKTPinchbackRMLigonAHChoYJHaeryLGreulichHReichMWincklerWLawrenceMSWeirBATanakaKEChiangDYBassAJLooAHoffmanCPrensnerJLiefeldTGaoQYeciesDSignorettiSMaherEKayeFJSasakiHTepperJEFletcherJATaberneroJBaselgaJTsaoMSDemichelisFRubinMAJannePADalyMJNuceraCLevineRLEbertBLGabrielSRustgiAKAntonescuCRLadanyiMLetaiAGarrawayLALodaMBeerDGTrueLDOkamotoAPomeroySLSingerSGolubTRLanderESGetzGSellersWRMeyersonM.The landscape of somatic copy-number alteration across human cancers. Nature2010;
463:899–905
17.
ZhaoLLiZChenWZhaiWPanJPangHLiX.H19 promotes endometrial cancer progression by modulating epithelial-mesenchymal transition. Oncol Lett2017;
13:363–9
18.
WangDWangDWangNLongZRenX.Long non-coding RNA BANCR promotes endometrial cancer cell proliferation and invasion by regulating MMP2 and MMP1 via ERK/MAPK signaling pathway. Cell Physiol Biochem2016;
40:644–56
19.
GuoQQianZYanDLiLHuangL.LncRNA-MEG3 inhibits cell proliferation of endometrial carcinoma by repressing notch signaling. Biomed Pharmacother2016;
82:589–94
20.
GuoCSongWQSunPJinLDaiHY.LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. J Biomed Sci2015;
22:100
21.
ZhouYXWangCMaoLWWangYLXiaLQZhao WShenJChenJ.Long noncoding RNA HOTAIR mediates the estrogen-induced metastasis of endometrial cancer cells via the miR-646/NPM1 axis. Am J Physiol Cell Physiol2018;
314:C690–c701
22.
ŁuczakASupernatAŁapińska-SzumczykSJachimowiczDMajewskaHGulczyńskiJŻaczekAJ.HOTAIR in relation to epithelial-mesenchymal transition and cancer stem cells in molecular subtypes of endometrial cancer. Int J Biol Markers2016;
31:e245–51
23.
QiaoQLiH.LncRNA FER1L4 suppresses cancer cell proliferation and cycle by regulating PTEN expression in endometrial carcinoma. Biochem Biophys Res Commun2016;
478:507–12
24.
OuyangDLiRLiYZhuX.A 7-lncRNA signature predict prognosis of uterine corpus endometrial carcinoma. J Cell Biochem2019;
120:18465–77
25.
LiuJMeiJWangYChenXPanJTongLZhangY.Development of a novel immune-related lncRNA signature as a prognostic classifier for endometrial carcinoma. Int J Biol Sci2021;
17:448–59
26.
ThorssonVGibbsDLBrownSDWolfDBortoneDSOu YangTHPorta-PardoEGaoGFPlaisierCLEddyJAZivECulhaneACPaullEOSivakumarIKAGentlesAJMalhotraRFarshidfarFColapricoAParkerJSMoseLEVoNSLiuJLiuYRaderJDhankaniVReynoldsSMBowlbyRCalifanoACherniackADAnastassiouDBedognettiDMokrabYNewmanAMRaoAChenKKrasnitzAHuHMaltaTMNoushmehrHPedamalluCSBullmanSOjesinaAILambAZhouWShenHChoueiriTKWeinsteinJNGuinneyJSaltzJHoltRARabkinCSLazarAJSerodyJSDemiccoEGDisisMLVincentBGShmulevichI.The immune landscape of cancer. Immunity2018;
48:812–30.e14
27.
DanilovaLHoWJZhuQVithayathilTDe Jesus-AcostaAAzadNSLaheruDAFertigEJAndersRJaffeeEMYarchoanM.Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol Res2019;
7:886–95
28.
RooneyMSShuklaSAWuCJGetzGHacohenN.Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell2015;
160:48–61
29.
MasieroMSimõesFCHanHDSnellCPeterkinTBridgesEMangalaLSWuSYPradeepSLiDHanCDaltonHLopez-BeresteinGTuynmanJBMortensenNLiJLPatientRSoodAKBanhamAHHarrisALBuffaFM.A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell2013;
24:229–41
30.
GaujouxRSeoigheC.A flexible R package for nonnegative matrix factorization. BMC Bioinform2010;
11:367
31.
CibulskisKLawrenceMSCarterSLSivachenkoAJaffeDSougnezCGabrielSMeyersonMLanderESGetzG.Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol2013;
31:213–9
32.
HänzelmannSCasteloRGuinneyJ.GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics2013;
14:1–15
Sanchez-VegaFMinaMArmeniaJChatilaWKLunaALaKCDimitriadoySLiuDLKanthetiHSSaghafiniaSChakravartyDDaianFGaoQBaileyMHLiangWWFoltzSMShmulevichIDingLHeinsZOchoaAGrossBGaoJZhangHKundraRKandothCBahceciIDervishiLDogrusozUZhouWShenHLairdPWWayGPGreeneCSLiangHXiaoYWangCIavaroneABergerAHBivonaTGLazarAJHammerGDGiordanoTKwongLNMcArthurGHuangCTwardADFrederickMJMcCormickFMeyersonMVan AllenEMCherniackADCirielloGSanderCSchultzN.Oncogenic signaling pathways in the cancer genome atlas. Cell2018;
173:321–37.e10
40.
SchreiberRDOldLJSmythMJ.Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (New YorkNY) 2011;
331:1565–70
41.
FangYFullwoodMJ.Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinform2016;
14:42–54
42.
HewardJALindsayMA.Long non-coding RNAs in the regulation of the immune response. Trends Immunol2014;
35:408–19
43.
AtianandMKHuWSatpathyATShenYRicciEPAlvarez-DominguezJRBhattaASchattgenSAMcGowanJDBlinJBraunJEGandhiPMooreMJChangHYLodishHFCaffreyDRFitzgeraldKA.A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation. Cell2016;
165:1672–85
44.
RanzaniVRossettiGPanzeriIArrigoniABonnalRJCurtiSGruarinPProvasiESuglianoEMarconiMDe FrancescoRGeginatJBodegaBAbrignaniSPaganiM.The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. Nat Immunol2015;
16:318–25
45.
HirataESahaiE.Tumor microenvironment and differential responses to therapy. Cold Spring Harb Perspect Med2017;
7:a026781
46.
Sadeghi RadHMonkmanJWarkianiMELadwaRO'ByrneKRezaeiNKulasingheA.Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev2021;
41:1474–98
47.
BeattyGLGladneyWL.Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res2015;
21:687–92
48.
JinKTYaoJYFangXLDiHMaYY.Roles of lncRNAs in cancer: focusing on angiogenesis. Life Sci2020;
252:117647
49.
LiGKryczekINamJLiXLiSLiJWeiSGroveSVatanLZhouJDuWLinHWangTSubramanianCMoonJJCieslikMCohenMZouW.LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol2021;
23:526–37
50.
EhmerUSageJ.Control of proliferation and cancer growth by the hippo signaling pathway. Mol Cancer Res2016;
14:127–40
51.
OttoTSicinskiP.Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer2017;
17:93–115
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
